# 503629766 12/30/2015

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3676397

		NEW ASSIGNMENT	NEW ASSIGNMENT				
NATURE OF CONVEY	ANCE:	ASSIGNMENT	ASSIGNMENT				
CONVEYING PARTY	DATA						
		Name	Execution Date				
TAUTONA GROUP L.	P.		03/27/2014				
RECEIVING PARTY D	ΑΤΑ						
Name:		ESTHETICS, LLC					
Street Address:	4040 CAI	MPBELL AVENUE					
Internal Address:	SUITE 11	10					
City:	MENLO	PARK					
State/Country:	CALIFOF	RNIA					
Postal Code:	94125						
PROPERTY NUMBER	RS Total: 1		-				
Property Type	e	Number					
Application Number:	14	1947409					
CORRESPONDENCE							
	•	14)246-4249 ba a mail addraca first, if that is un	ouccosoful it will be cont				
Correspondence will	be sent to t	14)246-4249 <b>he e-mail address first; if that is un</b> if that is unsuccessful, it will be sei					
Correspondence will using a fax number, i	be sent to t if provided;	he e-mail address first; if that is un					
<i>Correspondence will using a fax number, i</i> Phone: Email:	be sent to t if provided; 7 <sup>-</sup> pa	<i>he e-mail address first; if that is un if that is unsuccessful, it will be sei</i> 14 246-4500 atents_ip@allergan.com	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name	be sent to t if provided; 7 pa e: Al	<i>he e-mail address first; if that is un if that is unsuccessful, it will be sei</i> 14 246-4500 atents_ip@allergan.com LLERGAN, INC.	,				
<i>using a fax number, l</i> Phone: Email: Correspondent Name Address Line 1:	be sent to t if provided; 7 pa pa e: Al 25	<i>he e-mail address first; if that is un if that is unsuccessful, it will be sei</i> 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name	be sent to t if provided; 7 pa pa e: Al 25	<i>he e-mail address first; if that is un if that is unsuccessful, it will be sei</i> 14 246-4500 atents_ip@allergan.com LLERGAN, INC.	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4:	be sent to t if provided; 7 pa e: Al 25 IF	<i>he e-mail address first; if that is un if that is unsuccessful, it will be sei</i> 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4:	be sent to t if provided; 7 pa 25 25 25 16 NUMBER:	he e-mail address first; if that is un if that is unsuccessful, it will be sel 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612					
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER	be sent to t if provided; 7 pa 25 25 25 16 NUMBER:	he e-mail address first; if that is un if that is unsuccessful, it will be sel 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR)					
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1:	be sent to t if provided; 7 pa 25 25 25 16 NUMBER:	he e-mail address first; if that is un if that is unsuccessful, it will be set 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR) LINDA ALLYSON NASSIF					
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTEF SIGNATURE:	be sent to t if provided; 7 pa 25 25 25 16 NUMBER:	he e-mail address first; if that is un if that is unsuccessful, it will be set 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR) LINDA ALLYSON NASSIF /LINDA ALLYSON NASSIF/					
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTEF SIGNATURE: DATE SIGNED:	be sent to t if provided; 7 pa 25 25 17 NUMBER: 17 NUMBER:	he e-mail address first; if that is un if that is unsuccessful, it will be set 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR) LINDA ALLYSON NASSIF /LINDA ALLYSON NASSIF/ 12/30/2015	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTEF SIGNATURE: DATE SIGNED: Total Attachments: 11	be sent to t if provided; 7 pa 25 Al 25 IF NUMBER: R: R: uTona to Alin	he e-mail address first; if that is un if that is unsuccessful, it will be set 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR) LINDA ALLYSON NASSIF /LINDA ALLYSON NASSIF/ 12/30/2015 e#page1.tif	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 11 source=Assignment Tau source=Assignment Tau	be sent to t if provided; 7 pa 2 c: Al 25 IF NUMBER: R: NUMBER: R: NUMBER: R: NUMBER: Al IF	he e-mail address first; if that is un if that is unsuccessful, it will be set 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR) LINDA ALLYSON NASSIF /LINDA ALLYSON NASSIF/ 12/30/2015 e#page1.tif e#page2.tif e#page3.tif	,				
Correspondence will using a fax number, i Phone: Email: Correspondent Name Address Line 1: Address Line 4: ATTORNEY DOCKET I NAME OF SUBMITTER SIGNATURE: DATE SIGNED: Total Attachments: 11 source=Assignment Tau source=Assignment Tau	be sent to t if provided; 7 pa 7 pa 2 pa 2 pa 2 pa 2 pa 2 pa 2 pa	he e-mail address first; if that is un if that is unsuccessful, it will be set 14 246-4500 atents_ip@allergan.com LLERGAN, INC. 525 DUPONT DRIVE RVINE, CALIFORNIA 92612 19413 CON (COR) LINDA ALLYSON NASSIF /LINDA ALLYSON NASSIF/ 12/30/2015 e#page1.tif e#page2.tif e#page4.tif					

source=Assignment TauTona to Aline#page6.tif source=Assignment TauTona to Aline#page7.tif source=Assignment TauTona to Aline#page8.tif source=Assignment TauTona to Aline#page9.tif source=Assignment TauTona to Aline#page10.tif source=Assignment TauTona to Aline#page11.tif

#### PATENT APPLICATION ASSIGNMENT

This PATENT APPLICATION ASSIGNMENT (this "Assignment") is made and entered into as of the 27<sup>th</sup> day of March, 2014 by and between TauTona Group, L.P., a Delaware limited partnership ("Assignor"), as assignor, and Aline Aesthetics, LLC, a Delaware limited liability company ("Assignee"), as assignee. Assignee and Assignor are sometimes collectively referred to herein as the "Parties" and separately as a "Party." Capitalized terms used but not otherwise defined herein shall have the meaning assigned to such terms in the Asset Purchase Agreement (as defined below).

WHEREAS, Assignor and Assignee intend to enter into that certain Asset Purchase Agreement, dated on or around the date hereof, by and among Assignor, Assignee, Allergan Holdings France S.A.S., a société par actions simplifiée incorporated under the laws of France ("Allergan"), and the other parties named therein (the "Asset Purchase Agreement"), pursuant to which, among other things, Assignee will sell, assign and transfer the Assigned Patent Applications (as defined in the Asset Purchase Agreement and as listed on Exhibit A hereto) to Allergan;

WHEREAS, Assignor currently owns the Assigned Patent Applications; and

WHEREAS, in order to transfer the Assigned Patent Applications to Assignee prior to the consummation of the transactions contemplated by the Asset Purchase Agreement, Assignor has agreed to assign to Assignee all of Assignor's right, title and interest in and to the Assigned Patent Applications, pursuant to and subject to the terms and conditions of this Assignment.

NOW, THEREFORE, for good and valuable consideration, the receipt and legal sufficiency of which are hereby mutually acknowledged, Assignor and Assignee hereby agree as follows:

- 1. Assignor hereby sells, assigns and transfers, delivers, and conveys to Assignee (and its successors and assigns) all of Assignor's rights, title and interest in and to the Assigned Patent Applications and the inventions disclosed in such applications which are vested in the Assignee in respect of the United States and its territorial possessions and in all foreign countries, to all letters patent or similar legal protection in the United States and its territorial possessions and in states territorial possessions and in all foreign countries, to all letters patent or similar legal protection in the United States and its territorial possessions and in any and all foreign countries to be obtained for said invention by said application and any continuation, divisional, renewal, substitute or reissue thereof and any legal equivalent thereof in a foreign country for the full term or terms for which the same may be granted.
- 2. Assignor further covenants that the Assignee will, upon its request, be provided promptly with all pertinent facts and documents relating to the Assigned Patent Applications as may be known and accessible to the Assignor and will testify as to the same in any interference or litigation related thereto and will promptly execute and deliver to the Assignee or its legal representative any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce the Assigned Patent Applications, all at Assignee's expense.
- 3. Assignor shall promptly execute, deliver, acknowledge and record such assignments and other documents and take all such other actions as Assignee may reasonably

105611907 v2

12

request to memorialize or perfect to the assignment and transfer of the Assigned Patent Applications and other assets and rights assigned and transferred to Assignee pursuant to <u>Section 1</u> of this Assignment, and Assignee shall bear all fees, costs and expenses incurred in connection with the preparation, recordation and filing of any such assignments or other documents, or the performance of any such actions.

- 4. All of the terms and provisions of this Assignment shall be binding upon Assignor and its permitted successors and assigns and shall inure to the benefit of Assignee and its permitted successors and assigns.
- 5. This Assignment is executed for the purpose of evidencing and confirming the transfer of the Assigned Patent Applications from Assignor to Assignee
- 6. This Assignment shall be governed by and construed in accordance with the Laws of the State of California without giving effect to any choice or conflict of law provision or rule that would cause the application of the Laws of any jurisdiction other than the State of California.
- 7. Nothing in this Assignment, express or implied, is intended to confer upon any Third Party any rights, remedies, obligations or liabilities.
- 8. The Parties may execute this Assignment in one or more counterparts, each of which will be deemed an original and all of which, when taken together, will be deemed to constitute one and the same agreement. Any signature page hereto delivered by facsimile machine or by e-mail (including in portable document format (pdf), as a joint photographic experts group (jpg) file, or otherwise) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any amendment thereto and may be used in lieu of the original signatures for all purposes. Any Party that delivers such a signature page agrees to deliver promptly an original counterpart to the other Party that requests it.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the Parties hereto have caused this Assignment to be executed by their duly authorized representatives as of the date first written above.

TAUTON OUF. P By:

Name: Geoffrey Gurtner

Title: Managing Member

MENCS, LLC ALIN§ By:

Name: Geoffrey Gurtner

Title: Managing Member

[Signature Page to Patent Application Assignment]

# <u>Exhibit A</u>

\*

22

# **Assigned Patent Applications**

Case Number	Countr Y	Applicat ion Number	Filing Date	Pub Number	Pub Date	Applicat ion Status	App Title
192190- P	US	61/49836 4	6/17/201 1			Expired	NEEDLE FOR DELIVERY OF DERMAL FILLER THREADS
192190- US	US	14/12674 1	12/16/20 13			Pending	NEEDLE FOR DELIVERY OF DERMAL FILLER THREADS
192190- WO	WO	PCT/US20 12/04280 0	6/15/201 2	WO2012/1744 64	12/20/201 2	Expired	NEEDLE FOR DELIVERY OF DERMAL FILLER THREADS
192325- CA	СА	2791050	1/26/201 1	2791050	9/9/2011	Pending	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192325- P	US	61/30930 8	3/1/2010			Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192325- P2	US	61/34732 4	5/21/201 0			Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF

192325- P3	US	61/40516 0	10/20/20 10			Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192325 US	US	371 13/58190 2	2/15/201 3	2013- 0142731	6/6/2013	Pending	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192325- WO	WO	PCT/US20 11/02263 6	1/26/201 1	WO 2011/109129	9/9/2011	Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192357- AU	AU	20123182 83	10/10/20 12	2012- 318283	5/9/2013	Pending	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192357- P	US	61/54596 2	10/11/20 11			Expired	HIGH CONCENTRAT ION HYALURONIC ACID THREADS AND METHODS OF THEIR USE
192357- P2	US	61/56807 7	12/7/201 1			Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF

\*

192357- P3	US	61/64494 5	5/9/2012			Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192357- US	US	13/64905 1	10/10/20 12	2013- 0122068	5/16/2013	Pending	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192357- US2	US	13/86005 2	4/10/201 3	2013- 0226235	8/29/2013	Pending	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192357- WO	WO	PCT/US20 12/05961 8	10/10/20 12	WO2013/0558 32	4/18/2013	Publishe d	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE THEREOF
192359- P	US	61/30935 3	3/1/2010			Expired	THREADS OF HYALURONIC ACID AND METHODS OF USE THEREOF
192359- P2	US	61/34732 5	5/21/201 0			Expired	THREADS OF HYALURONIC ACID AND METHODS OF USE THEREOF
192359- P3	US	61/40517 1	10/20/20 10			Expired	THREADS OF HYALURONIC ACID AND METHODS OF USE THEREOF

•

'x1

192359- WO	wo	PCT/US20 11/02264 0	1/26/201 1	wo 2011/109130	9/9/2011	Expired	THREADS OF HYALURONIC ACID AND METHODS OF USE THEREOF
192360- AU	AU	20092881 18	9/2/2009	2009288118	3/11/201 0	Pending	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF
192360- CA	CA	2735173	9/2/2009	2735173	3/11/2010	Publishe d	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF
192360- EP	EP	09812153 .6	9/2/2009	2324064	5/25/2011	Publishe d	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF
192360- HK	нк	11112752 .0	11/24/20 11	HK158234		Publishe d	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF

. 3

e.

192360- JP	JP	2011- 525290	9/2/2009	2012-501391	1/19/2012	Publishe d	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF
192360- P	US	61/19086 6	9/2/2008			Expired	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF
192360- US	US	371 13/06091 9	5/19/201 1	2011- 0263724	10/27/201 1	Pending	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF
192360- WO	WO	PCT/US20 09/05570 4		WO2010/0280 25	3/11/2010	Inactive	THREADS OF HYALURONIC ACID AND/OR DERIVATIVE S, THEREOF, METHODS OF MAKING THEREOF AND USES THEREOF

ŝ

192361- CA	CA	2815141	10/13/20 11	2815141	4/26/201 2	Pending	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF PREPARATIO N AND USE THEREOF
192361- EP	EP	11776962 .0	10/13/20 11	2629809	8/28/2013	Publishe d	HYALURONIC ACID THREADS AND METHODS FOR PREPARING THE SAME
192361- P	US	61/40517 5	10/20/20 10			Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF PREPARATIO N AND USE THEREOF
192361- US	05	371 13/88051 5	7/3/2013	2013- 0274222	10/17/201 3	Publishe d	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF PREPARATIO N AND USE THEREOF
192361- WO	WO		10/13/20 11	WO2012/0543 11	4/26/2012	Expired	THREADS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF PREPARATIO N AND USE THEREOF
192396- P	US	61/40517 9	10/20/20 10			Expired	DERMAL FILLER THREADS AND METHODS OF USE THEREOF

¢ ×

×.

192396- US	υs	371 13/88050 2	7/3/2013	2013- 0303480	11/14/201 3	Pending	SOFT TISSUE AUGMENTATI ON THREADS AND METHODS OF USE THEREOF
192396- WO	wo	PCT/US20 11/05618 2	10/13/20 11	WO 2012/054301	4/26/2012	Expired	SOFT TISSUE AUGMENTATI ON THREADS AND METHODS OF USE THEREOF
193259- P	us	61/93201 6	1/27/201 4			Pending	SUBSTANCE DELIVERY DEVICE
193260- P	US	61/93216 4	1/27/201 4			Pending	SPHERICAL FORMS OF CROSS- LINKED HYALURONIC ACID AND METHODS OF USE
192395~ P	US	61/77800 8	3/12/201 3			Expired	CROSS- LINKED HYALURONIC ACID THREADS FOR TREATMENT OF STRIAE
192395- NO	ŴO	PCT/US20 14/02444 1	03/12/20 14			Pending	CROSS- LINKED HYALURONIC ACID THREADS FOR TREATMENT OF STRIAE
192393- P	US	61/77806 6	3/12/201 3			Expired	BLUNT NEEDLE FOR DELIVERY OF DERMAL FILLER THREADS

3) \$

\$

WO		PCT/US20 14/02483 6	03/12/20 14		Pending	BLUNT NEEDLE FOR DELIVERY OF DERMAL FILLER THREADS
----	--	---------------------------	----------------	--	---------	---

×.

đ